⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Intas Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Intas Pharmaceuticals
↗Ahmedabad, India
Intas Pharmaceuticals is a leading, vertically integrated global pharmaceutical company headquartered in Ahmedabad, India. Founded in 1977, the company specializes in the development, manufacturing, and marketing of generic therapeutic drugs, biosimilars, and active pharmaceutical ingredients (APIs). It operates a vast network of manufacturing facilities globally and maintains a significant presence in over 85 countries, primarily through its subsidiary, Accord Healthcare.
The company has grown significantly through both organic development and strategic acquisitions, such as the purchase of Teva Pharmaceuticals' assets in the UK and Ireland. Intas focuses on high-barrier generics and complex injectables, with a strong emphasis on R&D across therapeutic areas including oncology, immunology, nephrology, and neurology.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:$2.5B
Founded:1977
Ownership:private
Status:operating
FUNDING
Investors:ChrysCapital, Temasek Holdings, Capital International
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biosimilars, Injectables
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Accord Healthcare
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Nimish Chudgar - Joint MD and CEO
Binish Chudgar - Vice Chairman and Joint MD
Scientific Founders:Hasmukh Chudgar
LINKS
Website:inatspharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Intas Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.